Bank of Hawaii Has $492,000 Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Bank of Hawaii lowered its stake in DexCom, Inc. (NASDAQ:DXCM) by 33.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 7,334 shares of the medical device company’s stock after selling 3,666 shares during the quarter. Bank of Hawaii’s holdings in DexCom were worth $492,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in DXCM. Jennison Associates LLC grew its holdings in shares of DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after buying an additional 6,544,102 shares in the last quarter. Westfield Capital Management Co. LP boosted its position in DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after acquiring an additional 876,739 shares during the last quarter. Canada Pension Plan Investment Board grew its stake in shares of DexCom by 189.1% during the 2nd quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock worth $75,471,000 after acquiring an additional 435,401 shares in the last quarter. Intech Investment Management LLC raised its holdings in shares of DexCom by 2,083.0% in the third quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock valued at $25,967,000 after purchasing an additional 369,587 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in DexCom by 16.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock worth $276,538,000 after purchasing an additional 353,019 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity at DexCom

In other news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,431 shares of company stock worth $399,319. Company insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on DXCM shares. Wells Fargo & Company boosted their price target on shares of DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Robert W. Baird raised their price target on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. Stifel Nicolaus boosted their target price on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Piper Sandler reissued an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a research report on Monday, August 26th. Finally, Raymond James cut their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $104.59.

DexCom Price Performance

NASDAQ:DXCM opened at $77.83 on Tuesday. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The firm’s 50-day simple moving average is $70.76 and its 200 day simple moving average is $88.93. The firm has a market cap of $30.40 billion, a price-to-earnings ratio of 46.60, a P/E/G ratio of 2.23 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.